Bank of America’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,308,386
| Closed | -$7.64M | – | 8575 |
|
|
2022
Q4 | $7.64M | Buy |
1,308,386
+4,391
| +0.3% | +$23.1K | ﹤0.01% | 2952 |
|
|
2022
Q3 | $8.74M | Buy |
1,303,995
+83,454
| +7% | +$506K | ﹤0.01% | 2751 |
|
|
2022
Q2 | $5.14M | Buy |
1,220,541
+213,582
| +21% | +$845K | ﹤0.01% | 3361 |
|
|
2022
Q1 | $3.39M | Sell |
1,006,959
-299
| -0% | -$948 | ﹤0.01% | 4029 |
|
|
2021
Q4 | $3.17M | Buy |
1,007,258
+8,004
| +0.8% | +$26.6K | ﹤0.01% | 4104 |
|
|
2021
Q3 | $3.27M | Sell |
999,254
-6,904
| -0.7% | -$24.2K | ﹤0.01% | 3983 |
|
|
2021
Q2 | $4.25M | Sell |
1,006,158
-24,934
| -2% | -$106K | ﹤0.01% | 3667 |
|
|
2021
Q1 | $5.15M | Sell |
1,031,092
-846,236
| -45% | -$6.84M | ﹤0.01% | 3364 |
|
|
2020
Q4 | $23.7M | Buy |
1,877,328
+7,954
| +0.4% | +$90.7K | ﹤0.01% | 1726 |
|
|
2020
Q3 | $18.4M | Buy |
1,869,374
+1,731
| +0.1% | +$17.1K | ﹤0.01% | 1780 |
|
|
2020
Q2 | $18.6M | Buy |
1,867,643
+1,717
| +0.1% | +$16.5K | ﹤0.01% | 1668 |
|
|
2020
Q1 | $16.5M | Buy |
1,865,926
+75,760
| +4% | +$747K | ﹤0.01% | 1654 |
|
|
2019
Q4 | $16.5M | Buy |
1,790,166
+332,585
| +23% | +$2.36M | ﹤0.01% | 2064 |
|
|
2019
Q3 | $8.57M | Buy |
1,457,581
+694,975
| +91% | +$7.37M | ﹤0.01% | 2672 |
|
|
2019
Q2 | $9.15M | Buy |
762,606
+651,684
| +588% | +$7.01M | ﹤0.01% | 2640 |
|
|
2019
Q1 | $1.34M | Buy |
110,922
+70,103
| +172% | +$1.03M | ﹤0.01% | 4293 |
|
|
2018
Q4 | $512K | Buy |
40,819
+7,491
| +22% | +$103K | ﹤0.01% | 4914 |
|
|
2018
Q3 | $495K | Buy |
33,328
+115
| +0.3% | +$1.81K | ﹤0.01% | 4959 |
|
|
2018
Q2 | $558K | Sell |
33,213
-10,117
| -23% | -$196K | ﹤0.01% | 4844 |
|
|
2018
Q1 | $993K | Sell |
43,330
-23,134
| -35% | -$515K | ﹤0.01% | 4380 |
|
|
2017
Q4 | $1.72M | Buy |
66,464
+18,396
| +38% | +$370K | ﹤0.01% | 4088 |
|
|
2017
Q3 | $709K | Sell |
48,068
-1,571
| -3% | -$22.8K | ﹤0.01% | 4743 |
|
|
2017
Q2 | $692K | Sell |
49,639
-12,316
| -20% | -$182K | ﹤0.01% | 4683 |
|
|
2017
Q1 | $1.06M | Sell |
61,955
-226
| -0.4% | -$2.71K | ﹤0.01% | 4391 |
|
|
2016
Q4 | $640K | Buy |
62,181
+3,260
| +6% | +$29.8K | ﹤0.01% | 4644 |
|
|
2016
Q3 | $596K | Buy |
58,921
+423
| +0.7% | +$4.62K | ﹤0.01% | 4505 |
|
|
2016
Q2 | $657K | Buy |
58,498
+3,243
| +6% | +$41.3K | ﹤0.01% | 4473 |
|
|
2016
Q1 | $755K | Sell |
55,255
-53,915
| -49% | -$776K | ﹤0.01% | 4305 |
|
|
2015
Q4 | $2.07M | Buy |
109,170
+9,116
| +9% | +$198K | ﹤0.01% | 3768 |
|
|
2015
Q3 | $1.88M | Buy |
100,054
+48
| +0% | +$816 | ﹤0.01% | 3825 |
|
|
2015
Q2 | $1.49M | Buy |
100,006
+6
| +0% | +$91 | ﹤0.01% | 3761 |
|
|
2015
Q1 | $1.51M | Buy |
100,000
+93,060
| +1,341% | +$1.3M | ﹤0.01% | 3471 |
|
|
2014
Q4 | $92K | Buy |
+6,940
| New | +$89.6K | ﹤0.01% | 5951 |
|
|
2014
Q3 | – | Sell |
-28,310
| Closed | -$286K | – | 8234 |
|
|
2014
Q2 | $286K | Buy |
+28,310
| New | +$273K | ﹤0.01% | 5203 |
|
Bank of America's CNCE Position: Q1 2023 in Review
Bank of America sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,308,386 shares — an estimated $7.64M sold.
Bank of America first reported a position in CNCE in Q2 2014 and held it in 34 quarters. The position peaked at $23.7M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Bank of America reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Bank of America sold 1,308,386 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.64M.
- Bank of America first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 34 quarters.
- Bank of America's Concert Pharmaceuticals, Inc. position peaked at $23.7M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.